Compare AstraZeneca plc (AZN) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs VanEck Junior Gold Miners — how do they compare? AstraZeneca plc trades at $158.41 (market cap $248.14B), while VanEck Junior Gold Miners trades at $119.25. The key difference: AstraZeneca plc pays a 2.01% dividend while VanEck Junior Gold Miners pays none, and VanEck Junior Gold Miners is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | GDXJ | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $209.48 | $156.19 |
52-Week Low | $147.06 | $71.22 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
GDXJ (VanEck Junior Gold Miners ETF) trades at $119.44, up 0.56% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed sentiment with institutional selling by Amundi reducing its stake by 50.5% in the latest quarter (Defense World, August 6, 2026). Recent underperformance versus peers and gold ETFs highlights challenges in the junior gold mining sector.
Outlook remains cautious due to high RSI levels suggesting overbought conditions and sector-specific headwinds. Investment opportunity hinges on gold price momentum, but risks include Federal Reserve policy uncertainty and competitive pressure from senior miners. Analyst sentiment is neutral with concerns about portfolio composition and small-cap exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
